Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 5 versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 5 versus TEXACORT.
DEXONE 0.5 vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
0.5 mg orally once daily, with gradual taper to lowest effective dose
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid